EUVIMEDEUVIMED entdecken
Crossref

Preclinical Study of Carbonic Anhydrase IX and Prostate-Specific Membrane Antigen Bispecific Probe for Synergistic Targeting of Hypoxia and Neovasculature

Yihong Chen iD, Zhe Zhang, Yaofeng Xiao iD, Maohua Rao, Zhenyu Yang, Zi Wang, Yu Zhang, Yue Feng, Liang Cai

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.5c01880 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Yihong Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Second Affiliated Hospital of Chongqing Medical University, No. 74 Linjiang Rd., Yuzhong District, Chongqing 4000…. Hauptthemen laut MEDLINE: Carbonic Anhydrase IX, Glutamate Carboxypeptidase II, Antigens, Surface, Antigens, Neoplasm. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing Municipality, Central Guidance for Local Science and Technology Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The heterogeneous expression of tumor biomarkers limits the diagnostic performance of single-target imaging agents. Carbonic anhydrase IX (CAIX) is highly expressed in hypoxic regions of clear cell renal cell carcinoma (ccRCC) and multiple solid tumors, whereas prostate-specific membrane antigen (PSMA) is specifically upregulated in tumor-associated neovasculature. Both targets have been implicated in tumor metastasis and poor clinical outcomes. This study aimed to design and evaluate a novel bispecific PET tracer, [68Ga]Ga-PCA, targeting both CAIX and PSMA, with the goal of achieving improved tumor-specific uptake. Subcutaneous xenograft models were established in nude mice by inoculation with OS-RC-2, PC3-PIP, and HEK-293 cells. PET/CT imaging and biodistribution studies were performed following intravenous administration of [68Ga]Ga-PCA. Target specificity was evaluated via competitive blocking assays employing excess unlabeled ligand. Immunohistochemical staining was performed to validate the expression profiles of the targets within the tumors. After being labeled with gallium-68, [68Ga]Ga-PCA showed favorable physicochemical properties, such as a high radiolabeling yield (>80%), radiochemical purity over 95%, good stability in vitro, and an albumin-binding rate of 93.44 ± 0.81%. PET/CT imaging revealed pronounced and specific tracer accumulation in both OS-RC-2 and PC3-PIP tumor models. In OS-RC-2 tumors (PSMA+/CAIX+), the SUVmax (13.10 ± 0.84) was higher than those of the single-target tracers [68Ga]Ga-DOTA-NY104 (5.31 ± 0.77) and [68Ga]Ga-PSMA (2.31 ± 0.49) at 60 min postinjection. An excess of unlabeled DOTA-NY104, a PSMA-targeted ligand, or a mix of the two ligands can block the uptake of [68Ga]Ga-PCA. These results demonstrate that the tracer can bind to both targets at once. In conclusion, [68Ga]Ga-PCA is a bispecific PET tracer that targets both hypoxic tumor cells and tumor neovasculature by binding to both CAIX and PSMA. The probe exhibited significant specificity, advantageous imaging contrast, and robust blocking validation, indicating its potential for molecular imaging of malignancies, including clear cell renal cell carcinoma (ccRCC).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carbonic Anhydrase IXGlutamate Carboxypeptidase IIAntigens, SurfaceAntigens, NeoplasmCarcinoma, Renal CellProstatic NeoplasmsKidney NeoplasmsAnimalsHumansMaleMiceMice, NudeCell Line, TumorGallium RadioisotopesPositron Emission Tomography Computed TomographyTissue DistributionHEK293 CellsRadiopharmaceuticalsXenograft Model Antitumor Assays

Stichwörter der Autor:innen

CAIXPETPSMAclear cell renal cell carcinomaheterodimer

Substanzen

Carbonic Anhydrase IXGlutamate Carboxypeptidase IIGallium RadioisotopesAntigens, SurfaceFOLH1 protein, humanAntigens, NeoplasmCA9 protein, humanRadiopharmaceuticalsGallium-68

Autor:innen und Institutionen

  • Department of Nuclear Medicine, The Second Affiliated Hospital of Chongqing Medical University, No. 74 Linjiang Rd., Yuzhong District, Chongqing 400010, China.

ORCID-Profile: Yihong Chen, Yaofeng Xiao

Förderung

  • Natural Science Foundation of Chongqing Municipality
  • Central Guidance for Local Science and Technology Development

Zitieren

APA

Chen, Y., Zhang, Z., Xiao, Y., Rao, M., Yang, Z., Wang, Z., Zhang, Y., Feng, Y., & Cai, L. (2026). Preclinical Study of Carbonic Anhydrase IX and Prostate-Specific Membrane Antigen Bispecific Probe for Synergistic Targeting of Hypoxia and Neovasculature. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01880

Vancouver

Chen Y, Zhang Z, Xiao Y, Rao M, Yang Z, Wang Z, et al. Preclinical Study of Carbonic Anhydrase IX and Prostate-Specific Membrane Antigen Bispecific Probe for Synergistic Targeting of Hypoxia and Neovasculature. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01880

BibTeX
@article{Chen2026,
  author = {Chen, Yihong and Zhang, Zhe and Xiao, Yaofeng and Rao, Maohua and Yang, Zhenyu and Wang, Zi and Zhang, Yu and Feng, Yue and Cai, Liang},
  title = {Preclinical Study of Carbonic Anhydrase IX and Prostate-Specific Membrane Antigen Bispecific Probe for Synergistic Targeting of Hypoxia and Neovasculature},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.5c01880}
}
Kostenlos starten →